EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Different Biomarkers of Response to Treatment with Selective Jak-1 Inhibitors in Rheumatoid Arthritis

Maurizio Benucci, Francesca Li Gobbi, Paola Fusi, Arianna Damiani, Edda Russo, Serena Guiducci, Mariangela Manfredi, Valentina Grossi, Maria Infantino, Amedeo Amedei

Frontiers in Bioscience-Landmark · 23.08.2023 · 28 (8)

DOI: 10.31083/j.fbl2808176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 23.08.2023. Verfasst von Maurizio Benucci und 9 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Unit, Hospital S. Giovanni di Dio, Azienda USL-Toscana Centro, 50068 Florence, Italy. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Janus Kinases, Receptors, Urokinase Plasminogen Activator. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Rheumatoid arthritis (RA) is a systemic autoimmune disease that causes progressive joint damage. The Janus kinase (JAK) inhibitors (JAK-I) represent a new therapeutic option for RA patients, blocking the intracellular JAK-STAT pathway. Today, no studies have been conducted to determine whether new biomarkers could better reflect disease activity in patients treated with JAK-I than traditional disease activity indicators. Thus, the aim of our study was to determine additional disease activity biomarkers in RA patients receiving selective JAK-1 inhibitors. Methods: we enrolled 57 patients with RA: 34 patients were treated with Upadacitinib (UPA) and 23 patients with Filgotinib (FIL). All patients were evaluated for clinimetry with DAS28 and Crohn’s Disease Activity Index (CDAI), number of tender and swollen joints, Visual Analogic Scale (VAS), Physician Global Assessment (PhGA), and Health Assessment Questionnaire (HAQ), at baseline and at the 12th week of treatment. Lymphocyte subpopulations, complete blood count, erythrocyte sedimentation rate (ESR), C-Reactive Protein (CRP), anti-cyclic citrullinated peptide antibodies (APCA), rheumatoid factor (RF) IgM, interleukin 6 (IL-6), circulating calprotectin (cCLP), tumor necrosis factor α (TNFα), soluble urokinase Plasminogen Activator Receptor (suPAR), complement functional activity were measured at baseline and after the 12th week of treatment. Results: in both groups of patients, we documented a significant reduction in the clinimetric parameters DAS28, CDAI, number of tender joints, number of swollen joints, VAS, PhGA, and HAQ. Moreover, significant differences were reported for laboratory parameters of ESR, CRP, IL-6, suPAR, cCLP, and PLT/L ratio in both groups. However, no difference was demonstrated between the two groups for changes in renal, hepatic, and lipid parameters. Conclusions: the suPAR and cCLP levels may lead towards a different therapeutic choice between UPA and FIL, with the expression of two different RA pathophenotypes directing FIL towards a lymphocyte-poor form and UPA towards a myeloid form of RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidJanus KinasesReceptors, Urokinase Plasminogen ActivatorHumansBiomarkersC-Reactive ProteinInterleukin-6Signal TransductionSTAT Transcription Factors

Stichwörter der Autor:innen

JAK inhibitorsbiomarkersfilgotinibrheumatoid arthritisupadacitinib

Substanzen

BiomarkersC-Reactive ProteinInterleukin-6Janus KinasesReceptors, Urokinase Plasminogen ActivatorSTAT Transcription Factors

Autor:innen und Institutionen

  • Rheumatology Unit, Hospital S. Giovanni di Dio, Azienda USL-Toscana Centro, 50068 Florence, Italy.
  • Department of Experimental and Clinical Medicine, University of Florence, 50139 Florence, Italy.
  • Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, Azienda USL-Toscana Centro, 50068 Florence, Italy.

Zitieren

APA

Benucci, M., Gobbi, F. L., Fusi, P., Damiani, A., Russo, E., Guiducci, S., Manfredi, M., Grossi, V., Infantino, M., & Amedei, A. (2023). Different Biomarkers of Response to Treatment with Selective Jak-1 Inhibitors in Rheumatoid Arthritis. Frontiers in Bioscience-Landmark, 28(8). https://doi.org/10.31083/j.fbl2808176

Vancouver

Benucci M, Gobbi FL, Fusi P, Damiani A, Russo E, Guiducci S, et al. Different Biomarkers of Response to Treatment with Selective Jak-1 Inhibitors in Rheumatoid Arthritis. Frontiers in Bioscience-Landmark. 2023;28(8). doi:10.31083/j.fbl2808176

BibTeX
@article{Benucci2023,
  author = {Benucci, Maurizio and Gobbi, Francesca Li and Fusi, Paola and Damiani, Arianna and Russo, Edda and Guiducci, Serena and Manfredi, Mariangela and Grossi, Valentina and Infantino, Maria and Amedei, Amedeo},
  title = {Different Biomarkers of Response to Treatment with Selective Jak-1 Inhibitors in Rheumatoid Arthritis},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2023},
  volume = {28},
  number = {8},
  doi = {10.31083/j.fbl2808176}
}
Kostenlos starten →